Raltegravir: A review of its pharmacokinetics, pharmacology and clinical studies

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 9, 2010, Pages 1151-1160

  Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

AIDS; Antiretroviral agents; HIV integrase; Raltegravir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; LAMOTRIGINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MIDAZOLAM; NEVIRAPINE; OMEPRAZOLE; PRAVASTATIN; RALTEGRAVIR; RIFABUTIN; RIFAMPICIN; RILPIVIRINE; RITONAVIR; TENOFOVIR; TIPRANAVIR;

CLINICAL STUDY; CLINICAL TRIAL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MEDICAL INFORMATION; MEDLINE; MYOPATHY; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SYSTEMATIC REVIEW;

CELL LINE; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; PYRROLIDINONES;

EID: 77955790197     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.513383     Document Type: Review

References (62)

1. FDA. Isentress; Prescribing Information. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/022145s014lbl.pdf. Version date: 26 March 2010
2. Hazuda D, Iwamoto M, Wenning L. Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annu Rev Pharmacol Toxicol 2009;49:377-394
3. Croxtall JD, Lyseng-Williamson KA, Perry CM. Raltegravir. Drugs 2008;68:131-138
4. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006;43:509-515
5. Lei HP, Ji W, Lin J, et al. Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. Br J Clin Pharmacol 2009;68:201-206
6. Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008;83:293-299
7. Molto J, Valle M, Mothe B, et al. Pharmacokinetics and safety of once-daily raltegravir (800mg) plus atazanavir (400 mg) in HIV-infected patients [abstract O-13]. 10th International workshop on clinical pharmacology of HIV therapy; 15-17 April 2009; Amsterdam, the Netherlands
8. Yilmaz A, Gisslen M, Spudich S, et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 2009;4:e6877
9. Calcagno A, Bonora S, Bertucci R, et al. Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. AIDS 2010;24:931-932
10. Bonora S, D'Avolio A, Simele M, et al. Steady-state raltegravir penetration in seminal plasma of healthy volunteers [abstract # 609]. 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, CA
11. Clavel C, Mandelbrot L, Marcelin AG, et al. Raltegravir concentrations in the cervico-vaginal compartment in HIV-1 infected women treated with raltegravir: DIVA 01 study [abstract # 608]. 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, CA
12. Molto J, Valle M, Back D, et al. Pharmacokinetics of once-daily raltegravir (800 mg) in plasma and PBMCs in HIV-infected patients [abstract #LB-01]. 11th International Workshop on Clinical Pharmacology of HIV Therapy; 7-9 April 2010; Sorrento, Italy
13. Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the HIV-1 integrase enzyme. Drug Metab Dispos 2007;35:1657-1663
14. Wenning LA, Petry AS, Kost JT, et al. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin Pharmacol Ther 2009;85:623-627
15. Iwamoto M, Hanley WD, Petry AS, et al. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. Antimicrob Agents Chemother 2009;53:1747-1752
16. Tommassi C, Nicastri E, Gallo AL, et al. Raltegravir and darunavir plasma pharmacokinetic in HIV-1-infeced patients with advanced liver disease [abstract #10]. 11th International Workshop on Clinical Pharmacology of HIV Therapy; 7-9 April 2010; Sorrento, Italy
17. Molto J, Sanz-Moreno J, Valle M, et al. Effect of hemodialysis on raltegravir clearance in HIV-infected patients with end stage renal disease [abstract #7]. 11th International Workshop on Clinical Pharmacology of HIV Therapy; 7-9 April 2010; Sorrento, Italy
18. Wiznia A, Samson P, Acosta E, et al.; IMPAACT P1066. Safety and efficacy of rlategravir in pediatric HIV infection: preliminary analysis from the international maternal pediatric adolescent AIDs clinical trial group, P1066 [abstract 881]. 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Canada
19. Nachman S, Acosta E, Samson P, et al.; the P1066 team. Interim results from IMPAACT P1066: raltegravir oral chewable tablet formulation in children 6 to 11 years [abstract # 161LB]. 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, CA
20. La Porte CJ, Back DJ, Blaschke T, et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther 2006;3:4-14
21. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007;369:1261-1269
22. Wenning LA, Hwang E, Nguyen B-Y, et al. Pharmacokinetic/pharmacodynamic (PK/PD) analyses for raltegravir (RAL) in phase III studies in treatment experienced HIV-infected patients following 48 weeks of treatment [abstract H-4054]. 48th Annual ICAAC/46th IDSA Meeting; 25-28 October 2008; Washington DC
23. McSharry J, Weng Q, Kulaway R, Drusano G. Dose range and dose fractionation studies for raltegravir pharmacodynamics in an in vitro hollow fiber infection model system [abstract O-09]. 10th International workshop on clinical pharmacology of HIV therapy; 15-17 April 2009; Amsterdam, the Netherlands
24. Burger DM, Colbers EPH, Van Luin M, Koopmans PP. AUC0-3h of raltegravir is correlated to AUC0-12h: a novel approach for therapeutic drug monitoring of raltegravir [abstract #41]. 11th International Workshop on Clinical Pharmacology of HIV Therapy; 7 - 9 April 2010; Sorrento, Italy
25. Iwamoto M, Kassahun K, Troyer MD, et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol 2008;48:209-214
26. Van Luin M, Colbers A, Verwey-Van Wissen CP, et al. The effect of raltegravir on the glucuronidation of lamotrigine. J Clin Pharmacol 2009;49:1220-1227
27. Anderson MS, Wenning LA, Moreau A, et al. Effect of raltegravir on the pharmacokinetics of oral contraceptives [abstract H-1758]. 47th Interscience Conference on Antimicrobial Agents and Chemconf-procapy; 17-20 September 2007; Chicago, USA
28. Fulco PP, Hynicka L, Rackley D. Raltegravir-based HAART regimen in a patient with large B-cell lymphoma. Ann Pharmacother 2010;44:377-382
29. Van Luin M, Colbers A, van Ewijk-Beneken-Kolmer EWJ, et al. Drug-drug interactions between raltegravir and pravastatin in healthy volunteers [abstract #29]. 11th International Workshop on Clinical Pharmacology of HIV Therapy; 7-9 April 2010; Sorrento, Italy
30. Burger DM, Magis-Escurra C, van den Berk GE, Gelinck LB. Pharmacokinetics of double-dose raltegravir in two patients with HIV infection and tuberculosis. AIDS 2010;24:328-330
31. Moreno A, Quereda C, Fortun J, et al. Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage. AIDS 2010;24:1231-1233
32. Bickel M, Anadol E, Vogel M, et al. Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir. J Antimicrob Chemother 2010;65:999-1004
33. Di BA, Rosso R, Siccardi M, et al. Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. J Antimicrob Chemother 2009;64:874-875
34. Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009;9:1946-1952
35. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374:796-806
36. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase iii trials. Clin Infect Dis 2010;50:605-612
37. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375:396-407
38. De Castro N, Braun J, Charreau I, et al. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis 2009;49:1259-1267
39. Papendorp SG, van den Berk GE. Preoperative use of raltegravir-containing regimen as induction therapy: very rapid decline of HIV-1 viral load. AIDS 2009;23:739
40. Working Group of the office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, version December 1, 2010. Available from: http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL. pdf. [Last accessed 7 July 2010]
41. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009;49:1441-1449
42. Cooper DA, Steigbigel RT, Lennox JL, et al. Review of cancer incidence in raltegravir (RAL) clinical trials [abstract 559]. 16th Conference on Retroviruses and Opportunistic Infections; 8 - 11 February 2009; Montreal, Canada
43. Vispo E, Mena A, Maida I, et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2010;65:543-547
44. Rockstroh J, Teppler H, Zhao J, et al. Hepatic safety & efficacy of raltegravir in patients co-infected with HIV and hepatitisB and/or C virus [abstract 662]. 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, CA
45. Zembower TR, Gerzenshtein L, Coleman K, Palella FJ Jr. Severe rhabdomyolysis associated with raltegravir use. AIDS 2008;22:1382-1384
46. Dori L, Buonomini AR, Viscione M, et al. A case of rhabdomiolysis associated with raltegravir use. AIDS 2010;24:473-475
47. Martinez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010;24:1697-1707
48. Wenning LA, Friedman EJ, Kost JT, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 2008;52:3253-3258
49. Iwamoto M, Wenning LA, Petry AS, et al. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2008;52:4338-4343
50. Anderson MS, Kakuda TN, Hanley W, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother 2008;52:4228-4232
51. Hanley WD, Wenning LA, Moreau A, et al. Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009;53:2752-2755
52. Iwamoto M, Wenning LA, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis 2008;47:137-140
53. Zhu L, Mahnke L, Butterton J, et al. Pharmacokinetics and safety of twice daily atazanavir 300 mg and raltegravir 400 mg in healthy subjects [abstract 696]. 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Canada
54. Anderson MS, Sekar V, Tomaka F, et al. Pharmacokinetic evaluation of darunavir/ritonavir and raltegravir in healthy subjects [abstract A-962]. 48th Annual ICAAC/46th IDSA Meeting; 25-28 October 2008; Washington DC
55. Rhame F, Long M, Acosta E. RAL-KAL: pharmacokinetics of coadminsitered raltegravir and lopinavir/ritonavir in healthy subjects [abstract TuPe0075]. 17th International AIDS Conference; 3-8 August 2008; Mexico City, Mexico
56. Luber A, Slowinski PD, Acosta E, et al. Steady-state pharmacokinetics (PK) of fosamprenavir (FPV) and raltegravir (RAL) alone and combined with unboosted and ritonavir-boosted FPV [abstract A1-1297]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12-15 September 2009; San Francisco, CA
57. Andrews E, Glue P, Fang J, et al. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Br J Clin Pharmacol 2010;69:51-57
58. Brainard DM, Petry A, Fang L, et al. Lack of a clinically important effect of rifabutin (RFB) on raltegravir (RAL) pharmacokinetics [abstract A1-1296]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12-15 September 2009; San Francisco, CA
59. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009;53:2852-2856
60. Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis 2009;48:489-492
61. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-Week Controlled Study. J Acquir Immune Defic Syndr 2007;46:125-133
62. Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009;52:350-356